Unlocking scalable & affordable regenerative medicine to reverse the root causes of degenerative diseases
Conveyxo develops RNA-enhanced exosomes designed to reduce inflammation, restore cellular balance, and address degenerative diseases at their biological roots.
Our Mission: Delivering Treatments for Degenerative Diseases Using the Body’s Natural Healing Messengers, Making Them Affordable and Accessible to All
We focus on extending healthspan, the years of life lived in good health, by augmenting the power of exosomes, tiny stem cell-derived vesicles that naturally carry anti-inflammatory and regenerative signals. These exosomes represent the next generation of cell-free therapies, and we uniquely enhance their therapeutic potential with additional payloads such as RNA.
The result? Potent, scalable, and affordable technology platform helps restore balance and regenerative capacity across multiple disease pathways.
Degenerative diseases challenge our society models
As people live longer, staying healthy throughout those extra years has become a growing challenge. While lifespans have increased, healthspan – the time spent in good health – has not kept up, largely due to the rise of inflammatory and degenerative diseases.
Modern lifestyles and longer lifespans have worsened age-related conditions, putting more stain on healthcare systems and reducing quality of life.
Our Technology Platform &
Therapeutic Focus
Personalized home care designed to support seniors in living safely,comfortably, and with the dignity they deserve.
Our exosomes come from a single donor Wharton’s-jelly mesenchymal stem cell line, immortalized to guarantee consistent potency batch after batch. One donor can produce 1 billion doses, while competing technologies would need 10²⁴ donors, creating high variability and non-pharma-grade results. Ours are also stable at -20 degrees for several months.
Proprietary perfused bioreactors enable industrial-scale production at costs 40x cheaper than competitors. This overcomes the common scaling challenges in regenerative medicine.
Our patented microfluidic-based loading technology is based on a temporary mechanical porosity of the exosomes for payload absorption (mechanoporation). This process enables the loading of cargo, such as RNA, into exosomes without altering their natural therapeutic properties, boosting efficacy while preserving their integrity. Competing methods often compromise exosome quality or increase rejection risk.
Our therapeutic pipeline is built on a platform that enhances the natural regenerative power of exosomes. By engineering RNA cargo and optimizing delivery, we aim to address the underlying drivers of inflammation and degenerative disease. Each stage of our process brings us closer to developing therapies that restore cellular health and improve long-term outcomes.
From Discovery to Clinical Translation
Investigating the biological mechanisms of exosomes and their regenerative potential.
Together, we design a plan that reflects health requirements, lifestyle, and family expectations—ensuring comfort, dignity, and independence.
Advancing preclinical programs that address musculoskeletal and metabolic degenerative diseases.